Küçük Hücre Dışı Akciğer Kanserinde Perioperatif Tedaviler

Authors

Hayrani Kaya

Synopsis

Perioperative systemic therapies in resectable non-small-cell lung cancer (NSCLC) aim to reduce postoperative recurrence and improve survival. This review discusses patient selection, staging, platinum-based chemotherapy, neoadjuvant chemoimmunotherapy, perioperative and adjuvant immunotherapy, and biomarker-directed adjuvant targeted therapy. Findings from CheckMate 816, KEYNOTE-671, AEGEAN, CheckMate 77T, ADAURA, and ALINA are evaluated alongside their study designs and limitations in clinical practice. Outcomes from trials with different populations and treatment components should not be compared directly. In EGFR-mutated disease, adjuvant chemotherapy should be assessed according to disease stage, recurrence risk, and patient fitness, while osimertinib should be considered in patients meeting the relevant molecular and stage criteria. Treatment strategies should be individualized through multidisciplinary assessment, taking resectability, molecular profile, toxicity, and patient preferences into account.

 

References

Zer A, Ahn MJ, Barlesi F, et al. Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2025;36(11):1245-1262. doi:10.1016/j.annonc.2025.08.003.

Forde PM, Spicer JD, Provencio M, et al. Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer. New England Journal of Medicine. 2025;393(8):741-752. doi:10.1056/NEJMoa2502931.

Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. Journal of Clinical Oncology. 2008;26(21):3552-3559. doi:10.1200/JCO.2007.13.9030.

Felip E, Altorki N, Zhou C, et al. Five-year survival outcomes with atezolizumab after chemotherapy in resected stage IB-IIIA non-small cell lung cancer (IMpower010): an open-label, randomized, phase III trial. Journal of Clinical Oncology. 2025;43(21):2343-2349. doi:10.1200/JCO-24-01681.

O’Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. The Lancet Oncology. 2022;23(10):1274-1286. doi:10.1016/S1470-2045(22)00518-6.

Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. New England Journal of Medicine. 2022;386(21):1973-1985. doi:10.1056/NEJMoa2202170.

Spicer JD, Garassino MC, Wakelee H, et al. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2024;404(10459):1240-1252. doi:10.1016/S0140-6736(24)01756-2.

Heymach JV, Harpole D, Mitsudomi T, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. New England Journal of Medicine. 2023;389(18):1672-1684. doi:10.1056/NEJMoa2304875.

Heymach JV, He J, Harpole D, et al. Perioperative durvalumab for resectable non-small cell lung cancer: updated outcomes from the phase III AEGEAN trial. Journal of Clinical Oncology. 2026. Online ahead of print. doi:10.1200/JCO-25-02659.

Cascone T, Awad MM, Spicer JD, et al. Perioperative nivolumab in resectable lung cancer. New England Journal of Medicine. 2024;390(19):1756-1769. doi:10.1056/NEJMoa2311926.

Forde PM, Provencio M, Girard N, et al. Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816 [kongre özeti]. Journal of Clinical Oncology. 2025;43(17_suppl):LBA8000. doi:10.1200/JCO.2025.43.17_suppl.LBA8000.

Tsuboi M, Herbst RS, John T, et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. New England Journal of Medicine. 2023;389(2):137-147. doi:10.1056/NEJMoa2304594.

Wu YL, Dziadziuszko R, Ahn JS, et al. Alectinib in resected ALK-positive non-small-cell lung cancer. New England Journal of Medicine. 2024;390(14):1265-1276. doi:10.1056/NEJMoa2310532.

Le Pechoux C, Pourel N, Barlesi F, et al. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-label, randomised, phase 3 trial. The Lancet Oncology. 2022;23(1):104-114. doi:10.1016/S1470-2045(21)00606-9.

Burdett S, Rydzewska L, Tierney JF, et al. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database of Systematic Reviews. 2016;10:CD002142. doi:10.1002/14651858.CD002142.pub4.

U.S. Food and Drug Administration. FDA approves atezolizumab as adjuvant treatment for non-small cell lung cancer. 15 October 2021. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-adjuvant-treatment-non-small-cell-lung-cancer. Erişim: 4 Ekim 2026.

European Medicines Agency. Tecentriq EPAR product information. https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq. Erişim: 4 Ekim 2026.

U.S. Food and Drug Administration. FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer. 26 January 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-adjuvant-treatment-non-small-cell-lung-cancer. Erişim: 4 Ekim 2026.

Published

November 16, 2026

License

License